1-9 of 9
Jeffrey M Venstrom, MD
Close
Sort by
Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1907.
https://doi.org/10.1182/blood-2019-123652
Published: 2019
Journal Articles

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Eugene C Kim, PhD, Jinzhen Fan, PhD, Christopher R Bolen, PhD, Alexandra Bazeos, MD PhD FRCPath, Yanwen Jiang, PhD, Sandhya Balasubramanian, MS, Rama Balakrishnan, PhD, Andrea Knapp, PhD, Kathryn Humphrey, BSc, Tina G Nielsen, MD PhD, Jeffrey M. Venstrom, MD PhD, Genevive Hernandez, PhD, Joseph N Paulson, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2788.
https://doi.org/10.1182/blood-2019-124687
Published: 2019
Journal Articles

Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma

Ehsan Tabari, PhD, Alexander F Lovejoy, PhD, Hai Lin, PhD, Christopher R Bolen, PhD, Seng Lor Saelee, BA, Joshua P Lefkowitz, David M. Kurtz, MD PhD, Patrik Vitazka, MD PhD, Jeffrey M. Venstrom, MD PhD, Tina G Nielsen, MD PhD, Joana M Parreira, MD, Daniel M Klass, PhD, Khai T Luong, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 490.
https://doi.org/10.1182/blood-2019-123633
Published: 2019
Journal Articles

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brian G. Till, MD, Steven I. Park, MD, Leslie L. Popplewell, MD, Andre Goy, MD, Elicia Penuel, PhD, Jeffrey M Venstrom, MD, Bo Liu, Guenter Fingerle-Rowson, MD PhD, John Byon, MD PhD, Paul Woodard, MD, M. Lia Palomba, MD
Journal: Blood
Blood (2015) 126 (23): 5104.
https://doi.org/10.1182/blood.V126.23.5104.5104
Published: 2015
Journal Articles

KIR and HLA Genotypes Influence Clinical Outcome in Multiple Myeloma Patients Treated with SAR650984 (Anti-CD38) in Combination with Lenalidomide and Dexamethasone

John Marra, BS, Juan Du, MD PhD, Jimmy Hwang, PhD, Jeffrey L Wolf, MD, Thomas G. Martin, MD, Jeffrey M Venstrom, MD
Journal: Blood
Blood (2014) 124 (21): 2126.
https://doi.org/10.1182/blood.V124.21.2126.2126
Published: 2014
Journal Articles

Delayed Hematopoietic Recovery After Autologous Stem Cell Transplantation In Patients Receiving Arsenic Trioxide-Based Therapy For Acute Promyelocytic Leukemia

Gabriel N. Mannis, MD, Lloyd E Damon, MD, Weiyun Z. Ai, MD, PhD, Charalambos Andreadis, MD, MS, Karin ML Gaensler, MD, Neel K. Gupta, M.D., Lawrence D. Kaplan, M.D., Andrew D. Leavitt, MD, Aaron C. Logan, MD, PhD, Rebecca L. Olin, MD, MS, Peter H. Sayre, MD, PhD, Catherine C Smith, MD, Jeffrey M Venstrom, MD, Thomas G Martin, III, MD
Journal: Blood
Blood (2013) 122 (21): 2172.
https://doi.org/10.1182/blood.V122.21.2172.2172
Published: 2013
Journal Articles

Natural Killer Cell Licensing Delineates NK “Helper/Repair” and NK “Effector/Suppressor” Subsets During Viral Infections

Can M. Sungur, Anthony E. Zamora, Ethan G. Aguilar, Yajarayma Tang-Feldman, Juan Du, Nicole Baumgarth, Mingyi Chen, MD, PhD, Claire Pomeroy, Jeffrey M. Venstrom, MD, William J. Murphy, PhD
Journal: Blood
Blood (2013) 122 (21): 13.
https://doi.org/10.1182/blood.V122.21.13.13
Published: 2013
Journal Articles

Donor KIR3DL1 and HLA-B Allotypes Control Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Fabio Giglio, MD, Ted A. Gooley, PhD, Jeffrey M Venstrom, MD, Meighan M Gallagher, LiHua Hou, PhD, Carolyn K Hurley, PhD, Tatiana Lebedeva, MD, PhD, Harriet Noreen, CHS, Raja Rajalingam, PhD, Elaine F Reed, PhD, Neng Yu, MD, Cynthia Vierra-Green, MS, Michael D Haagenson, MS, Mari Malkki, PhD, Effie W. Petersdorf, MD, Stephen Spellman, MBS, Katharine C. Hsu, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 349.
https://doi.org/10.1182/blood.V120.21.349.349
Published: 2012
Journal Articles

Lack of HLA Class I Ligands for Autologous Inhibitory KIR Is Associated with Improved Survival Following Autologous Stem Cell Transplant for Children with Neuroblastoma.

Jeffrey M Venstrom, MD, Junting Zheng, MA, Reenat S Hasan, BS, Karen E Danis, MA, Irene Y Cheung, ScD, Bo Dupont, MD, DSc, Nai Kong Cheung, MD, PhD, Katharine C Hsu, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3322.
https://doi.org/10.1182/blood.V112.11.3322.3322
Published: 2008